Buchumschlag

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Fang Yan, Pengshuang Shi, Shimin Wu, Jie Yang, Dejun Cui
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
von: David Bergman, et al.
Veröffentlicht: (2024)

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing
von: Tomohiro Fukuda, et al.
Veröffentlicht: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively?
von: David Laharie
Veröffentlicht: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
von: Matthias Lenfant, et al.
Veröffentlicht: (2024)

Letter: Over‐the‐scope clips in patients at high risk of rebleeding following upper gastrointestinal tract bleeding—The magic bullet for everyone? Authors'reply
von: Kai Song, et al.
Veröffentlicht: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis
von: Anthony Croft, et al.
Veröffentlicht: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
von: Jian Wang, et al.
Veröffentlicht: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
von: Vibeke Strande, et al.
Veröffentlicht: (2024)

Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people
von: Shuyao Song, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B
von: Jian Wang, et al.
Veröffentlicht: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
von: Zhuo Li, et al.
Veröffentlicht: (2024)

Letter: Over‐the‐scope clips in patients at high risk of re‐bleeding following upper gastrointestinal tract bleeding—The magic bullet for everyone?
von: Gabriel Allo, et al.
Veröffentlicht: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
von: Jian Wang, et al.
Veröffentlicht: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
von: Jiamei Wang, et al.
Veröffentlicht: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
von: Mingsi Zhang, et al.
Veröffentlicht: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
von: Christian P. Selinger, et al.
Veröffentlicht: (2024)

Letter: Enhancing patient support through social work—Addressing economic challenges and medication non‐adherence in liver disease management
von: Min Wu, et al.
Veröffentlicht: (2024)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Letter: Reflections on the role of over‐the‐scope clips in high‐risk upper gastrointestinal bleeding
von: Yajie Wang, et al.
Veröffentlicht: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
von: Elliot B. Tapper, et al.
Veröffentlicht: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
von: Ivan Arcari, et al.
Veröffentlicht: (2024)

Letter: Methodological Flaws and Clinical Gaps—A Critique of TAF / TDF 5‐Year Data in East Asian CHB
von: Zhiyao Shi, et al.
Veröffentlicht: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Letter: Baseline age on antiviral treatment may significantly influence the clinical response of children with chronic hepatitis B ‐ authors' reply
von: WenXian OuYang, et al.
Veröffentlicht: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
von: Hyeyeon Hong, et al.
Veröffentlicht: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
von: Leya Nedumannil, et al.
Veröffentlicht: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
von: Zhejin Shi, et al.
Veröffentlicht: (2026)

Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
von: María Chaparro, et al.
Veröffentlicht: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?
von: L. A. A. P. Derikx, et al.
Veröffentlicht: (2024)

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis
von: Manuel Barreiro‐de Acosta, et al.
Veröffentlicht: (2024)

Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study
von: Merle Claßen, et al.
Veröffentlicht: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
von: Lukas Burghart, et al.
Veröffentlicht: (2024)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography
von: Bo Li, et al.
Veröffentlicht: (2024)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
von: Giammarco Mocci, et al.
Veröffentlicht: (2024)